Syngulon

Rue Du Bois Saint Jean 15/1

4102 Seraing

BE

Syngulon

Foundation date

07/03/2013

Sector

#Biotechnology - other

Subsector

Syngulon is developing original genetic technologies to improve the efficiency of microorganisms.Syngulon has introduced a new genetic technology (US Patent 9,333,227, issued on May 10, 2016) for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.This issued patent is part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive basis.  

Upcoming events

Latest news

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    17 hours ago

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022

  • Pauwels Consulting takes over Science@Work

    Friday September 23rd 2022